Abbott Laboratories (ABT) SEC Filings & Earnings Calls

Foreign exchange impact on international sales.

“Comparable sales growth excludes impact of foreign exchange.”

Integration risk from Exact Sciences acquisition.

“Comparable sales growth includes prior and current year sales of Exact Sciences, acquired March 23, 2026.”

Execution risk in separating a major business segment; potential distraction and costs

“Separation of global nutrition business involves complex operational and regulatory steps.”

Loss of diversification benefits; remaining company more concentrated

“Nutrition business separation reduces product portfolio breadth.”

Ongoing litigation risk from remaining ~1,700 lawsuits with ~12,700 claimants; potential for additional settlements or adverse verdicts.

“Following these agreements, there are roughly 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants.” · word for word

NEC Litigation Risk

“Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC)... a plaintiff verdict awarding $495 million in damages.” · word for word

Integration Risk from Exact Sciences

“The acquisition of Exact Sciences has established Abbott's position in the cancer diagnostics market... The preliminary allocation of the fair value of the Exact Sciences acquisition is shown in the table below.” · word for word

Tax Dispute Risk

“In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.” · word for word

Nutrition segment continues to decline, particularly in the U.S. (-9.0% comparable), driven by pediatric (-10.7%) and adult (-6.4%) weakness.

“U.S. │ (9.0) │ │ (10.7) │ │ (6.4)” · word for word

NEC Litigation Risk

“Abbott is a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC)... the resolution of which could be material to Abbott's financial position, cash flows, or results of operations.”

IRS Tax Dispute Risk

“In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.” · word for word

Integration Risk from Exact Sciences Acquisition

“The acquisition of Exact Sciences is expected to establish Abbott's position in the cancer diagnostics market... The preliminary allocation of the fair value of the Exact Sciences acquisition is shown in the table below. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed and differe” · word for word

No material risk signals; routine governance and compensation plan updates.

Derivative lawsuit settlement reduces litigation risk, but financial terms not disclosed.

“Preliminary approval of settlement; final hearing pending.”

Integration risk from Exact Sciences acquisition may pressure near-term margins.

“Includes $0.20 of dilution related to the acquisition of Exact Sciences.” · word for word

Integration risk from large acquisition

“Acquisition of Exact Sciences may involve integration challenges”

Increased leverage from $20B debt issuance may pressure credit ratings

“Debt increased by $20B to fund acquisition”

Acquisition integration risk if Exact Sciences deal closes

“Proceeds intended to fund Exact Sciences acquisition”

Significant increase in debt leverage to fund acquisition

“$20 billion in new senior notes issued to fund Exact Sciences acquisition”

Integration risk from Exact Sciences acquisition

“Proceeds used to fund acquisition of Exact Sciences Corporation”

China Market Headwinds

“The 2025 and 2024 sales decreases were driven by continued lower demand for the company's portfolio of COVID-19 tests and challenging market conditions in China, including the impact of volume-based procurement programs.” · word for word

COVID-19 Testing Decline

“In 2025, 2024, and 2023, Abbott’s COVID-19 testing-related sales totaled $297 million, $747 million, and $1.6 billion, respectively.” · word for word

Pricing Pressure from Healthcare Payors

“Budgetary pressures on healthcare payors may also heighten the scope and severity of pricing pressures on Abbott’s products for the foreseeable future.” · word for word

Regulatory Compliance Costs

“Compliance with these laws and regulations is costly and materially affects Abbott’s business.” · word for word

Nutrition segment weakness in U.S. and international markets, with Q4 organic decline of 9.1%.

“Nutrition total reported (8.9)% in Q4, organic (9.1)%.”

Diagnostics revenue decline due to COVID-19 testing normalization, though ex-COVID organic growth slightly positive.

“Diagnostics total reported (2.5)% in Q4, organic (3.6)%, ex-COVID organic (0.2)%.”

Regulatory and antitrust approval risks; integration risk; financing risk.

“Completion subject to HSR Act waiting period, other regulatory approvals, and absence of material adverse effect on Exact Sciences.”

China VBP impact on Diagnostics

“Diagnostic Products sales continued to be impacted by the decline in COVID-19 testing-related sales and challenging market conditions in China, including the impact of volume-based procurement programs.” · word for word

NEC litigation

“Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC)... Two cases have gone to trial. In a Missouri state case, a jury awarded a plaintiff $495 million in damages.” · word for word

IRS tax dispute

“In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.” · word for word